iPSC-based drug screening for Huntington׳s disease

Human iPSC-based Cardiac Microphysiological System For Drug Screening Applications

Drug discovery and development are hampered by high failure rates attributed to the reliance on non-human animal models employed during safety and efficacy testing. A fundamental problem in this inefficient process is that non-human animal models cannot adequately represent human biology. Thus, there is an urgent need for high-content in vitro systems that can better predict drug-induced toxici...

Disease correction the iPSC way: advances in iPSC-based therapy.

Pluripotent stem cells possess the capacity for self-renewal and the ability to differentiate into all cell types of the three embryonic germ layers. Accordingly, given their potential use in regenerative medicine, they have long attracted the attention of researchers. Embryonic stem cells (ESCs) represent the model pluripotent stem cell population. However, the use of ESCs in regenerative ther...

Applying Bioinfomatics Strategies in Huntingtons Disease Research

New Platforms For Drug Screening And Toxicology: Necessity Or Need?

The liver is the largest internal organ in the human body that is responsible for more than 500 vital functions, including biosynthesis of major plasma proteins, immunity against infectious pathogens, balancing energy metabolism and xenobiotics biotransformation (1). One of the main functions of the liver is an important role in drug metabolism (2). Since developing new drug compounds into mark...

Huntingtin and the molecular pathogenesis of Huntingtons disease

Huntington’s disease (HD) is a late-onset neurodegenerative disorder that is caused by a CAG repeat expansion in the IT15 gene, which results in a long stretch of polyglutamine close to the amino-terminus of the HD protein huntingtin (htt). The normal function of htt, and the molecular mechanisms that contribute to the disease pathogenesis, are in the process of being elucidated. In this review...